Study register · detail
Pure cannabidiol in the treatment of malignant migrating partial seizures in infancy: a case report.
No direction reported
Samplen = 1
Summary
Case report (n=1): In a 10-month-old infant with malignant migrating partial epilepsy of infancy (pharmacoresistant epileptic encephalopathy), the addition of pure cannabidiol to existing antiepileptic therapy led to sustained seizure reduction and developmental progress. Limitation: single case without control, no causality derivable, hypothesis-generating only.
Quality profile
Sample size
★★★★★
Blinding
—
Effect size
—
Citations / year
—
Authors
Share
Abstract
<h4>Background</h4>Malignant migrating partial seizures in infancy is a devastating pharmacoresistent epileptic encephalopathy of unknown etiology characterized by onset in the first 6 months of life, continuous migrating focal seizures with corresponding multifocal electroencephalographic discharges, developmental deterioration, and early mortality. Recent widespread interest in the nonpsychoactive component of the cannabis plant, cannabidiol, as a potential treatment for refractory devastating epilepsies has led to individual trials initiated by families or physicians in states that have legalized medical Cannabis with anecdotal success.<h4>Patient description</h4>We describe a now 10-month-old boy with malignant migrating partial seizures in infancy who made developmental gains and demonstrated sustained seizure reduction with the addition of cannabidiol to his antiepileptic regimen.<h4>Conclusion</h4>This report supports a role for cannabidiol in the treatment of malignant migrating partial seizures in infancy.
The impediment to action advances action.